{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:12:57Z","timestamp":1792732377122,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AR043369"],"award-info":[{"award-number":["R01 AR043369"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01 CA163222"],"award-info":[{"award-number":["P01 CA163222"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AR072304"],"award-info":[{"award-number":["R01 AR072304"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000861","name":"Burroughs Wellcome Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000861","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012331","name":"LEO Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005294","name":"Massachusetts General Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005294","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005190","name":"Melanoma Research Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006691","name":"Harvard Medical School","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jaad.2025.08.008","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T15:46:22Z","timestamp":1754667982000},"page":"1456-1463","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Type 2 immunity links eczematous and lichenoid eruptions caused by immune checkpoint inhibitors"],"prefix":"10.1016","volume":"93","author":[{"given":"Marjan","family":"Azin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parisa","family":"Farokh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"McGarry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie W.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Roster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Rashdan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Rajeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Khattab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher Jayee","family":"Thang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalynn M.","family":"Nazarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven T.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yevgeniy R.","family":"Semenov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shadmehr","family":"Demehri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2025.08.008_bib1","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1634\/theoncologist.2014-0422","article-title":"The evolving role of immune checkpoint inhibitors in cancer treatment","volume":"20","author":"Pennock","year":"2015","journal-title":"The oncologist"},{"key":"10.1016\/j.jaad.2025.08.008_bib2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejca.2019.04.035","article-title":"The evolving landscape of \u2018next-generation\u2019immune checkpoint inhibitors: a review","volume":"117","author":"Mazzarella","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaad.2025.08.008_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.779915","article-title":"Advances in knowledge and management of immune-related adverse events in cancer immunotherapy","volume":"13","author":"Olsen","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.jaad.2025.08.008_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1071983","article-title":"Cutaneous manifestations associated with immune checkpoint inhibitors","volume":"14","author":"Watanabe","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaad.2025.08.008_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.804597","article-title":"Holistic approach to immune checkpoint inhibitor-related adverse events","volume":"13","author":"Poto","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaad.2025.08.008_bib6","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.clindermatol.2019.10.015","article-title":"The life-threatening eruptions of immune checkpoint inhibitor therapy","volume":"38","author":"Coleman","year":"2020","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaad.2025.08.008_bib7","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1016\/j.jid.2022.04.020","article-title":"Cutaneous toxicities associated with immune checkpoint inhibitors: an observational, pharmacovigilance study","volume":"142","author":"Le","year":"2022","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2025.08.008_bib8","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/jamadermatol.2021.0326","article-title":"Patterns of cutaneous and noncutaneous immune-related adverse events among patients with advanced cancer","volume":"157","author":"Thompson","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2025.08.008_bib9","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis primers"},{"key":"10.1016\/j.jaad.2025.08.008_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.570752","article-title":"Incidence of skin and respiratory immune-related adverse events correlates with specific tumor types in patients treated with checkpoint inhibitors","volume":"10","author":"Rose","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jaad.2025.08.008_bib11","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaad.2022.12.048","article-title":"Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort study","volume":"88","author":"Zhang","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2025.08.008_bib12","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jaad.2019.08.045","article-title":"BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors","volume":"82","author":"Ali","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2025.08.008_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.991433","article-title":"Checkpoint inhibitor immune-related adverse events: a focused review on autoantibodies and B cells as biomarkers, advancements and future possibilities","volume":"13","author":"Taylor","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaad.2025.08.008_bib14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/jamadermatol.2021.5476","article-title":"Association of cutaneous immune-related adverse events with increased survival in patients treated with anti\u2013programmed cell death 1 and anti\u2013programmed cell death ligand 1 therapy","volume":"158","author":"Tang","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2025.08.008_bib15","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.humpath.2023.04.016","article-title":"Immune checkpoint inhibitor-induced cutaneous toxicities: a review of histopathologic and clinical features","volume":"140","author":"Martel","year":"2023","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jaad.2025.08.008_bib16","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2025.08.008_bib17","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor\u2013related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2025.08.008_bib18","doi-asserted-by":"crossref","first-page":"728","DOI":"10.3390\/jcm10040728","article-title":"The clinical and histopathological features of cutaneous immune-related adverse events and their outcomes","volume":"10","author":"Hashimoto","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.jaad.2025.08.008_bib19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/DAD.0000000000000688","article-title":"Lichenoid dermatologic toxicity from immune checkpoint blockade therapy: a detailed examination of the clinicopathologic features","volume":"39","author":"Tetzlaff","year":"2017","journal-title":"The Am J Dermatopathology"},{"key":"10.1016\/j.jaad.2025.08.008_bib20","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/jid.2009.42","article-title":"Lichenoid tissue reaction\/interface dermatitis: clinical and histological perspectives","volume":"129","author":"Sontheimer","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2025.08.008_bib21","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0190-9622(89)70174-2","article-title":"Lichenoid dermatitis: a clinicopathologic and immunopathologic review of sixty-two cases","volume":"21","author":"Oliver","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2025.08.008_bib22","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1600-0625.2009.00919.x","article-title":"Effector pathways during eczematous dermatitis: where inflammation meets cell death","volume":"18","author":"Kerstan","year":"2009","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaad.2025.08.008_bib23","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1172\/JCI9199","article-title":"T cell\u2013mediated Fas-induced keratinocyte apoptosis plays a key pathogenetic role in eczematous dermatitis","volume":"106","author":"Trautmann","year":"2000","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.jaad.2025.08.008_bib24","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.3390\/ijms24033038","article-title":"Comprehensive insight into lichen planus immunopathogenesis","volume":"24","author":"Vicic","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaad.2025.08.008_bib25","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/sj.jid.5700085","article-title":"IL-13-stimulated human keratinocytes preferentially attract CD4+ CCR4+ T cells: possible role in atopic dermatitis","volume":"126","author":"Purwar","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2025.08.008_bib26","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/1523-1747.ep12480966","article-title":"High frequency of IL-4\u2013producing CD4+ allergen-specific T lymphocytes in atopic dermatitis lesional skin","volume":"97","author":"van der Heijden","year":"1991","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2025.08.008_bib27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jdermsci.2014.07.010","article-title":"The panoply of \u03b1\u03b2T cells in the skin","volume":"76","author":"Nomura","year":"2014","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaad.2025.08.008_bib28","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/jamadermatol.2015.2","article-title":"Immunologic overlap of helper T-cell subtypes 17 and 22 in erythrodermic psoriasis and atopic dermatitis","volume":"151","author":"Moy","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"7968","key":"10.1016\/j.jaad.2025.08.008_bib29","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41586-023-06217-y","article-title":"PD-1 maintains CD8 T cell tolerance towards cutaneous neoantigens","volume":"619","author":"Damo","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2025.08.008_bib30","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1158\/1078-0432.CCR-15-2872","article-title":"Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy","volume":"22","author":"Goldinger","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2025.08.008_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2024.06.224","article-title":"208 Dupilumab for managing cutaneous immunotherapy toxicities does not impact mortality","volume":"144","author":"Khattab","year":"2024","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2025.08.008_bib32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/1203475420943260","article-title":"Cutaneous immune-related adverse events (irAEs) to immune checkpoint inhibitors: a dermatology perspective on management","volume":"25","author":"Muntyanu","year":"2021","journal-title":"J Cutan Med Surg"},{"issue":"9","key":"10.1016\/j.jaad.2025.08.008_bib33","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/ced\/llae060","article-title":"Cutaneous immune-related adverse events: incidence rates, risk factors and association with extracutaneous toxicity\u2013a prospective study of 189 patients treated with checkpoint inhibitors at a Spanish tertiary care hospital","volume":"49","author":"Juan-Carpena","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2025.08.008_bib34","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/imr.13257","article-title":"Cutaneous immune-related adverse events from immune checkpoint inhibitor therapy: moving beyond \u201cmaculopapular rash\u201d","volume":"318","author":"Allais","year":"2023","journal-title":"Immunological Rev"},{"key":"10.1016\/j.jaad.2025.08.008_bib35","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jamadermatol.2023.3003","article-title":"Cutaneous adverse events and cancer survival prognosis with immune checkpoint inhibitor treatment: a systematic review and meta-analysis","volume":"159","author":"Du","year":"2023","journal-title":"Jama Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.08.008_bib36","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/bjd\/ljae053","article-title":"Cancer type and histology influence cutaneous immunotherapy toxicities: a multi-institutional cohort study","volume":"191","author":"Wan","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2025.08.008_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.965550","article-title":"Incidence and factors associated with cutaneous immune-related adverse events to immune check point inhibitors: an ambispective cohort study","volume":"13","author":"Luangnara","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jaad.2025.08.008_bib38","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3740","article-title":"Bullous pemphigoid associated with anti-programmed cell death protein 1 and anti-programmed cell death ligand 1 therapy: a review of the literature","volume":"101","author":"Tsiogka","year":"2021","journal-title":"Acta dermato-venereologica"},{"key":"10.1016\/j.jaad.2025.08.008_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd8636","article-title":"Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses","volume":"13","author":"Lo","year":"2021","journal-title":"Sci translational Med"},{"key":"10.1016\/j.jaad.2025.08.008_bib40","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1007\/s10875-012-9683-2","article-title":"Increased B7-H1 expression on peripheral blood T cells in oral lichen planus correlated with disease severity","volume":"32","author":"Zhou","year":"2012","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaad.2025.08.008_bib41","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/CJI.0b013e318247a4e7","article-title":"PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer","volume":"35","author":"Dulos","year":"2012","journal-title":"J Immunother"},{"key":"10.1016\/j.jaad.2025.08.008_bib42","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/ijd.13540","article-title":"Histopathological aspects of cutaneous erythematous-papular eruptions induced by immune checkpoint inhibitors for the treatment of metastatic melanoma","volume":"56","author":"Perret","year":"2017","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2025.08.008_bib43","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jaad.2020.04.105","article-title":"Dermatologic toxicities to immune checkpoint inhibitor therapy: a review of histopathologic features","volume":"83","author":"Ellis","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2025.08.008_bib44","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/jamadermatol.2016.2226","article-title":"Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti\u2013programmed cell death 1 and anti\u2013programmed cell death ligand 1 immunotherapy","volume":"152","author":"Shi","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2025.08.008_bib45","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/ni1165","article-title":"Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4","volume":"6","author":"Probst","year":"2005","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaad.2025.08.008_bib46","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.4049\/jimmunol.1700216","article-title":"The innate cytokines IL-25, IL-33, and TSLP cooperate in the induction of type 2 innate lymphoid cell expansion and mucous metaplasia in rhinovirus-infected immature mice","volume":"199","author":"Han","year":"2017","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2025.08.008_bib47","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/jdv.18879","article-title":"Cutaneous lichenoid drug eruptions: a narrative review evaluating demographics, clinical features and culprit medications","volume":"37","author":"Maul","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2025.08.008_bib48","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/cup.13454","article-title":"Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14+ and CD16+ monocytes driving an innate immune response","volume":"46","author":"Curry","year":"2019","journal-title":"J Cutan Pathol"},{"issue":"6","key":"10.1016\/j.jaad.2025.08.008_bib49","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007324","article-title":"Management of immune-related cutaneous adverse events with dupilumab","volume":"11","author":"Kuo","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaad.2025.08.008_bib50","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jdcr.2022.12.013","article-title":"Lichenoid-granulomatous drug reactions to dupilumab: a report of 2 cases","volume":"33","author":"Rehan","year":"2023","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaad.2025.08.008_bib51","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jid.2021.06.040","article-title":"Immune checkpoint blockade and skin toxicity pathogenesis","volume":"142","author":"Ma","year":"2022","journal-title":"J Invest Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2025.08.008_bib52","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15623","article-title":"Dupilumab for the treatment of pembrolizumab-induced bullous pemphigoid: a case report","volume":"35","author":"Pop","year":"2022","journal-title":"Dermatol Ther"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225025964?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225025964?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:26:57Z","timestamp":1791880017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225025964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0190962225025964"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.08.008","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Type 2 immunity links eczematous and lichenoid eruptions caused by immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}